December 19, 2011

Sanofi Completes Divestiture of Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.

 

Sanofi Completes Divestiture of Dermik Dermatology Unit to Valeant Pharmaceuticals International, Inc.

Paris, France – December 19, 2011 – Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that it has completed the divestiture of its dermatology business, Dermik, to Valeant Pharmaceuticals International Inc. (NYSE/TSX: VRX) (“Valeant”), for a total cash consideration of US $422.5 million. Valeant is a pharmaceutical company focused on the neurology and dermatology therapeutic areas, based in Mississauga, Ontario, Canada.